Fox Business - The Power to Prosper
Search Site

GlaxoSmithKline

Chimerix announces clinical trials of antiviral Ebola drugs

FBN’s Charles Payne, A&G Capital CIO and President Hilary Kramer, Hedgeye Risk Management CEO Keith McCullough and TPNN.com News Director Scottie Nell Hughes discuss the state of Ebola drug stocks.

Read More

  1. Tiny implantable devices the future of medicine?

    GlaxoSmithKline Global R&D chairman Moncef Slaoui on the development of bioelectronic medicines.

  2. Market check: P, MRK, GSK

    FBN’s Lauren Simonetti with the latest on the markets.

  3. Market check: MRK, GSK , GM

    FBN’s Lauren Simonetti with the latest on the markets.

  4. Is it too late for investors to get on the Apple bandwagon?

    JohnsonBrunetti President Joel Johnson, Gary Goldberg Financial Services President Oliver Pursche and AverageJoeOptions.com founder Todd Horwitz on the outlook for stocks.

  5. UK regulators eye Glaxo

    FBN’s Jo Ling Kent on UK regulators bearing down on pharma giant GlaxoSmithKline .

  6. China charges ex-China GlaxoSmithKline head with bribery

    FBN’s Liz MacDonald on GlaxoSmithKline ’s alleged bribery charges.

  7. Chinese police to brief media on GlaxoSmithKline

    FBN’s Liz MacDonald on the latest on the GlaxoSmithKline bribery probe.

  8. The next golden age of M&A

    Citigroup Institutional Clients Group vice Chairman Leon Kalvaria gives his outlook for the M&A market.

  9. AstraZeneca Plans Spin-Offs

    AstraZeneca announced faster-than-expected progress of its experimental cancer drugs and plans to spin off billions of dollars of non-core assets as it staked a clai...

  10. Zimmer to Buy Biomet In $13.35B Deal

    Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...

  11. What the GSK , Novartis Deal Means for Biotech

    The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pha...

  12. Pharma Deal Frenzy: A Bid to Boost Profits

    High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...

  1. Rep. Burgess: Use money from ObamaCare to fight Ebola

    Rep. Michael Burgess (R-Texas) explains why he believes money from ObamaCare should be used to fight Ebola.

  2. Hot action in Ebola stocks

    FBN’s Liz MacDonald on investors backing companies that are developing drugs to combat the Ebola virus.

  3. Pod takes futuristic approach to napping

    Podtime owners Paul Grindrod and Jon Gray on inventing pods for napping.

  4. What is the risk of an Ebola outbreak in the U.S.?

    NIH’s Allergy and Infectious Diseases Director Dr. Anthony Fauci on the Ebola outbreak in West Africa.

  5. Ebola vaccine on the way?

    GlaxoSmithKline VP Donna Altenpohl on the company’s Ebola vaccine trial.

  6. Pandora shares get boost from ‘buy’ rating

    FBN’s Adam Shapiro breaks down the day in the markets.

  7. More trouble ahead for GSK

    FBN’s Liz MacDonald on GlaxoSmithKline ’s new bribery allegations.

‹ Prev12345Next ›
Freebase CC-BY
Source: GlaxoSmithKline on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL